Lantern Pharma
Update in progressLTRN (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Lantern Pharma Inc focuses on discovery and development of oncology drugs. Its pipeline includes LP-300 in Phase 2 for never-smokers with NSCLC adenocarcinoma; LP-184 in Phase 1a for advanced/metastatic solid tumors and CNS cancers; and LP-284 in Phase 1 for non-Hodgkin lymphomas. STAR-001 is preclinical for glioblastoma and other CNS cancers. It also runs an ADC program and AI-driven collaborations with Oregon Therapeutics (XCE853), TTC Oncology (TTC-352), and Actuate Therapeutics. Based in Dallas, TX.
Company score
- Sentiment
- 0.29
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.15
- Governance
- 0.02
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.05
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.17
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEOMr. Panna Sharma
- Founded2013
- Employees16
- Websitewww.lanternpharma.com
Identifiers
- ISINUS51654W1018
- FIGIBBG00GM6LK17
- CUSIP51654W101
- CIK0001763950